DES: friend or foe?

The current FDA approved stents (CYPHER and TAXUS) have been associated with late stent thrombosis (LST) (>30days following implantation) however, the mechanisms predictive of LST are poorly understood. Pathologic studies are one of the best methods for detailed analysis of morphologic changes that occur after placement of Drug Eluting Stents to determine the causes of LST.

We have studies at autopsy 83 patients (117 lesions) with DES in place for > 30 days implanted in patients with coronary artery disease. Of 33 lesions with either luminal thrombus (n=25 lesions) or organized thrombus (n=8 lesions) 6 lesions (5 patients) showed a hypersensitivity reaction (5 Cypher and 1 Taxus).

These stent had been in place from 112 to 940 days; three patient died suddenly and two presented with acute myocardial infarction. From these data it appears that the response is limited to the area of the stent and that there is extensive eosinophilic and T-cell infiltration. There may or may not be a granulomatous reaction.

Other morphologic changes that predispose stent thrombosis are malapposition (n=8), stenting of bifurcation lesions (n=7), AMI patients (n=8), and overlapping stents (n=4). All showed delayed healing, which is further exaggerated either from turbulent flow at malapposition or bifurcation sites or poor healing at sites of plaque rupture, and overlapping stents. Excessive length (>30 mm) is a correlate of LST as well as presence of uncovered stent struts. Uniformly all cases with thrombi have presence of fibrin, poor stent coverage by neointima, and less endothelialization.

All 78 lesions that were patent (and DES was not the cause of death) and had been in place for >30 days showed less neointima as compared to bare metal stents (BMS) thus suggesting that DES are effective in reducing neointimal thickness. A parameter, which is uniformly observed in BMS is that the neointimal formation (smooth muscle cells in matrix) around the circumference of the stent tends to be uniform in distribution. In DES there is heterogeneity of healing with areas showing excessive fibrin and others with smooth muscle cells within matrix and uneven luminal endothelialization.

Cypher and Taxus stents although use different drug and coatings, both reduce neointimal formation from delayed healing. However, there are inherent differences in the response to each of the stents in man with fibrin deposition being more frequent in Taxus stent while inflammation especially eosinophilic infiltrate and giant cell reaction being greater in the Cypher stent.

One can conclude from these histologic studies that because of underlying atherosclerotic plaque morphology differences, variability in healing from patient to patient, and a hypersensitivity in some patients; DES technology may have to be tailored to individual patient characteristics, rather than one stent fits all.

Notes

This presentation was made at the ESC Congress 2007 in Vienna.

The European Society of Cardiology (ESC):

The ESC represents nearly 53,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

The ESC achieves this through a variety of scientific and educational activities including the coordination of: clinical practice guidelines, education courses and initiatives, pan-European surveys on specific disease areas and the ESC Annual Congress, the largest medical meeting in Europe. The ESC also works closely with the European Commission and WHO to improve health policy in the EU.

The ESC comprises 3 Councils, 5 Associations, 19 Working Groups, 50 National Cardiac Societies and an ESC Fellowship Community (Fellow, FESC; Nurse Fellow, NFESC). For more information on ESC Initiatives, Congresses and Constituent Bodies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lab-grown tumor organoids predict patient response to CAR T cell therapy